These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19015251)

  • 21. Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.
    Bergmann-Leitner ES; Duncan EH; Mease RM; Angov E
    Malar J; 2012 Sep; 11():315. PubMed ID: 22958482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii.
    Kedzierski L; Black CG; Goschnick MW; Stowers AW; Coppel RL
    Infect Immun; 2002 Dec; 70(12):6606-13. PubMed ID: 12438332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge.
    Kedzierski L; Black CG; Coppel RL
    Infect Immun; 2000 Oct; 68(10):6034-7. PubMed ID: 10992516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen--the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1.
    Ma C; Wang L; Webster DE; Campbell AE; Coppel RL
    Appl Microbiol Biotechnol; 2012 Apr; 94(1):151-61. PubMed ID: 22170105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development.
    Miyata T; Harakuni T; Tsuboi T; Sattabongkot J; Ikehara A; Tachibana M; Torii M; Matsuzaki G; Arakawa T
    Infect Immun; 2011 Oct; 79(10):4260-75. PubMed ID: 21807905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolation and Characterization of Vaccine Candidate Genes Including
    Kim SH; Bae YA; Seoh JY; Yang HJ
    Korean J Parasitol; 2017 Jun; 55(3):255-265. PubMed ID: 28719950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice.
    Yoshida S; Araki H; Yokomine T
    Infect Immun; 2010 Feb; 78(2):595-602. PubMed ID: 19901059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) and their role in immunity to malaria.
    Tian JH; Good MF; Hirunpetcharat C; Kumar S; Ling IT; Jackson D; Cooper J; Lukszo J; Coligan J; Ahlers J; Saul A; Berzofsky JA; Holder AA; Miller LH; Kaslow DC
    Parasite Immunol; 1998 Jun; 20(6):263-78. PubMed ID: 9651928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection.
    Petritus PM; Burns JM
    J Immunol; 2008 Jan; 180(1):444-53. PubMed ID: 18097046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration.
    Cherif MS; Shuaibu MN; Kurosaki T; Helegbe GK; Kikuchi M; Yanagi T; Tsuboi T; Sasaki H; Hirayama K
    Vaccine; 2011 Nov; 29(48):9038-50. PubMed ID: 21939717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polyspecific malaria antibodies present at the time of infection inhibit the development of immunity to malaria but antibodies specific for the malaria merozoite surface protein, MSP1, facilitate immunity.
    Zhang W; Liu XQ; Xu H; Good MF
    Parasite Immunol; 2002 May; 24(5):233-41. PubMed ID: 12060317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam.
    Murhandarwati EE; Wang L; Black CG; Nhan DH; Richie TL; Coppel RL
    Infect Immun; 2009 Oct; 77(10):4510-7. PubMed ID: 19620342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and Evaluation of a Cryopreserved Whole-Parasite Vaccine in a Rodent Model of Blood-Stage Malaria.
    Stanisic DI; Ho MF; Nevagi R; Cooper E; Walton M; Islam MT; Hussein WM; Skwarczynski M; Toth I; Good MF
    mBio; 2021 Oct; 12(5):e0265721. PubMed ID: 34663097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of 19-kDa C-terminal region of merozoite surface protein-1-specific antibody responses in neonatal pups by maternally derived 19-kDa C-terminal region of merozoite surface protein-1-specific antibodies but not whole parasite-specific antibodies.
    Stanisic DI; Martin LB; Gatton ML; Good MF
    J Immunol; 2004 May; 172(9):5570-81. PubMed ID: 15100300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
    Lynch MM; Cernetich-Ott A; Weidanz WP; Burns JM
    Clin Vaccine Immunol; 2009 Mar; 16(3):293-302. PubMed ID: 19116303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Merozoite surface protein-1 of Plasmodium yoelii fused via an oligosaccharide moiety of cholera toxin B subunit glycoprotein expressed in yeast induced protective immunity against lethal malaria infection in mice.
    Miyata T; Harakuni T; Taira T; Matsuzaki G; Arakawa T
    Vaccine; 2012 Jan; 30(5):948-58. PubMed ID: 22119928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the 19-kDa region of merozoite surface protein 1 and whole-parasite-specific maternal antibodies in directing neonatal pups' responses to rodent malaria infection.
    Stanisic DI; Martin LB; Good MF
    J Immunol; 2003 Nov; 171(10):5461-9. PubMed ID: 14607952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
    Wang L; Goschnick MW; Coppel RL
    Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii.
    Eslava I; Payares G; Pernia BM; Holder AA; Spencer LM
    Malar J; 2010 Feb; 9():46. PubMed ID: 20146804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite.
    Kang Y; Calvo PA; Daly TM; Long CA
    J Immunol; 1998 Oct; 161(8):4211-9. PubMed ID: 9780195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.